论文部分内容阅读
目的探究恩度联合化疗治疗晚期非小细胞肺癌效果观察。方法对照组给予化疗治疗,包括NP方案(长春瑞滨+顺铂)、TP/C方案(多西他赛+顺铂/卡铂)、GP/C方案(吉西他滨+顺铂/卡铂)。观察组在此基础上给予恩度治疗,2个疗程后评价两组临床疗效及不良反应。结果观察组临床总有效率和疾病控制率分别为54.55%和90.91%,均高于对照组的40.91%和77.27%;观察组Ⅰ-Ⅳ级的药物不良反应发生率均明显低于对照组,差异有统计学意义(P<0.05)。结论恩度联合化疗治疗晚期非小细胞肺癌,临床效果确切,药物不良反应小,无耐药性,明显延长患者生存期,值得临床应用推广。
Objective To investigate the effect of combined endometriosis chemotherapy for advanced non-small cell lung cancer. Methods The control group was given chemotherapy, including NP regimen (vinorelbine + cisplatin), TP / C regimen (docetaxel + cisplatin / carboplatin), GP / C regimen (gemcitabine + cisplatin / carboplatin). On the basis of this observation group, Endue treatment was given. After two courses of treatment, the clinical efficacy and adverse reactions in both groups were evaluated. Results The total clinical effective rate and disease control rate in the observation group were 54.55% and 90.91%, respectively, which were higher than those in the control group (40.91% and 77.27%, respectively). The adverse drug reaction rates in the observation group were significantly lower than those in the control group The difference was statistically significant (P <0.05). Conclusions Endood combined with chemotherapy for advanced non-small cell lung cancer has definite clinical effect, small adverse drug reaction and no drug resistance, prolongs survival time obviously and is worth popularizing in clinic.